In the last trading session, 3.63 million Esperion Therapeutics Inc (NASDAQ:ESPR) shares changed hands as the company’s beta touched 0.66. With the company’s per share price at $1.20 changed hands at -$0.02 or -1.64% during last session, the market valuation stood at $237.84M. ESPR’s last price was a discount, traded about -228.33% off its 52-week high of $3.94. The share price had its 52-week low at $0.69, which suggests the last value was 42.5% up since then. When we look at Esperion Therapeutics Inc’s average trading volume, we note the 10-day average is 4.88 million shares, with the 3-month average coming to 5.57 million.
Analysts gave the Esperion Therapeutics Inc (ESPR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.88. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended ESPR as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight.
Esperion Therapeutics Inc (NASDAQ:ESPR) trade information
Instantly ESPR was in red as seen at the end of in last trading. With action 30.63%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -45.45%, with the 5-day performance at 30.63% in the green. However, in the 30-day time frame, Esperion Therapeutics Inc (NASDAQ:ESPR) is 34.41% up. Looking at the short shares, we see there were 27.95 million shares sold at short interest cover period of 4.76 days.
The consensus price target for the stock as assigned by Wall Street analysts is 8, meaning bulls need an upside of 85.0% from its current market value. According to analyst projections, ESPR’s forecast low is 8 with 8 as the target high. To hit the forecast high, the stock’s price needs a -566.67% plunge from its current level, while the stock would need to soar -566.67% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 40.11%. The 2025 estimates are for Esperion Therapeutics Inc earnings to increase by 40.18%.
ESPR Dividends
Esperion Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-05.
Esperion Therapeutics Inc (NASDAQ:ESPR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.57% of Esperion Therapeutics Inc shares while 59.30% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 59.65%. There are 59.30% institutions holding the Esperion Therapeutics Inc stock share, with WASATCH ADVISORS LP the top institutional holder. As of 2024-06-30, the company held 8.9319% of the shares, roughly 16.86 million ESPR shares worth $37.44 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.4068% or 13.98 million shares worth $31.04 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 6.68 shares estimated at $8.01 million under it, the former controlled 3.37% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 3.12% of the shares, roughly 6.18 shares worth around $7.42 million.
